Ironwood Pharmaceuticals, Inc. (IRWD)

NASDAQ: IRWD · USD

$3.63

+0.12 (+3.3%)· Recorded snapshot

Market cap	599M
Revenue (ttm)	389.3M
Net income (ttm)	129.9M
EPS (ttm)	$0.79
Shares out	165.2M
P/E (trailing)	4.6x
P/E (forward)	2.9x
Volume	1,233,317
Beta	0.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 389.3M
Net income (ttm): 129.9M
EPS (ttm): $0.79
P/E (trailing): 4.6x
P/E (forward): 2.9x
Market cap: 599M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E2.9

P25 13.4P50 20.2P75 35.7

Trailing P/E4.6

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROIC65.7

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All IRWD indicators

Market & fundamental data

Available fields

255

Groups with data

Currency

USD

Showing 255 of 255 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001446847
Company name	Ironwood Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	46333X108
Earnings date	2026-11-09
Earnings time	bmo
Employees	100
Employees change	-153
Employees growth	-60.47%
Enterprise value	$916.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1998
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2010-02-03
Is primary listing	Yes
Is SPAC	No
ISIN number	US46333X1081
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$599M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$3.63
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	IRWD
U.S. state	Massachusetts
Website	https://ironwoodpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	4.65x
Average P/E ratio (5Y)	77.71x
Earnings yield	21.77%
EV/Earnings	6.97x
EV/EBIT	3.83x
EV/EBITDA	3.8x
EV/FCF	4.88x
EV/Sales	2.33x
FCF / EV yield	20.5%
FCF yield	31.59%
Forward EV/Sales	1.91x
Forward P/E	2.86x
Forward P/S	1.24x
Industry forward P/E	13.87x
Industry P/E	173.94x
Lynch fair value	$3.95
Lynch upside	10.97%
P/(FCF - SBC) ratio	3.43x
P/(OCF - SBC) ratio	3.43x
P/E ratio	4.59x
P/FCF ratio	3.17x
P/OCF ratio	3.17x
P/S ratio	1.51x
Price/EBITDA ratio	2.47x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	60.69%
EBITDA margin	61.16%
Effective tax rate	37.38%
FCF margin	47.66%
Gross margin	77.22%
Operating margin	60.69%
Pretax margin	53.27%
Profit margin	33.36%
Profit per employee	$1.3M
Profitable quarters	2
Profitable years	2
Revenue per employee	$3.9M
ROA	47.02%
ROA (5Y)	16.28%
ROCE	93.66%
ROIC	65.68%
ROIC (5Y)	39.55%
SBC / revenue	3.68%
Tax / revenue	19.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	125.68%
EPS growth (QoQ)	29.17%
EPS growth 5Y	-24.09%
EPS growth quarters	2
EPS growth years	2
FCF growth	519.84%
FCF growth (QoQ)	1,037.98%
FCF growth 3Y	-11.02%
FCF growth 5Y	-3.98%
Gross profit growth	48.46%
Gross profit growth (Q)	46.48%
Gross profit growth 3Y	-6.91%
Gross profit growth 5Y	-2.8%
Net income growth (Q)	117.34%
Net income growth (QoQ)	25.8%
Net income growth 5Y	-23.9%
Net income growth quarters	2
Net income growth years	2
OCF growth	518.83%
OCF growth (QoQ)	1,037.98%
OCF growth 3Y	-11.02%
OCF growth 5Y	-3.99%
Operating income growth	155.76%
Operating income growth (Q)	75.96%
Operating income growth 3Y	-2.25%
Operating income growth 5Y	1.15%
Revenue growth	26.19%
Revenue growth (Q)	32.62%
Revenue growth (QoQ)	6.14%
Revenue growth 10Y	6.2%
Revenue growth 3Y	-3.05%
Revenue growth 5Y	-1.18%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1,000
Depreciation and amortization	$1.8M
EBIT	$236.3M
EBITDA	$238.1M
EPS	$0.79
FCF per share	$1.12
Financing cash flow	$-199.6M
Free cash flow	$185.6M
Free cash flow minus SBC	$171.2M
Gross profit	$300.6M
Income taxes	$77.5M
Investing cash flow	$-1,000
Net borrowing	$-200M
Net cash flow	$-13.7M
Net income	$129.9M
Operating cash flow minus SBC	$171.2M
Operating income	$236.3M
Revenue	$389.3M
Stock-based compensation	$14.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-2.34
Book value per share	$-0.98
Debt / EBITDA	1.65
Debt / FCF	2.14
Interest coverage	7.23
Long-term assets	$85.9M
Long-term liabilities	$414.1M
Net cash (debt)	$-317.7M
Net cash / market cap	-54.09%
Net debt / EBITDA	1.33
Net debt / FCF	1.71
Piotroski F-Score	7
Property, plant and equipment	$11.4M
Shareholders' equity	$-161.8M
Tangible book value	$-163.5M
Tangible book value per share	$-0.99
Total assets	$285.1M
Total cash	$79.1M
Total debt	$396.9M
Total liabilities	$447M
WACC	5.34%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.24
Current assets	$199.2M
Current liabilities	$32.9M
Current ratio	6.06
Net working capital	$90.5M
Quick ratio	5.84
Working capital	$166.3M
Working capital turnover	6.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.27%
Dividend yield	0%
Shareholder yield	-3.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-72.49%
10Y return CAGR	-10.53%
10Y total return	-67.13%
150-day SMA	$3.95
15Y price change	-74.93%
15Y return CAGR	-7.72%
15Y total return	-70.05%
1D price change	3.28%
1M price change	-13.2%
1M total return	-13.2%
1W price change	-1.24%
1W total return	-1.24%
1Y price change	119.94%
1Y return CAGR	120.06%
1Y total return	119.94%
20-day SMA	$3.64
200-day SMA	$4.00
3M price change	-8.31%
3M total return	-8.31%
3Y price change	-59.22%
3Y return CAGR	-25.84%
3Y total return	-59.22%
50-day SMA	$3.98
50-day SMA vs 200-day SMA	50under200
52-week high	$5.78
52-week high date	2026-01-02
52-week low	$1.47
52-week low date	2025-10-30
5Y price change	-71.07%
5Y return CAGR	-21.97%
5Y total return	-71.07%
6M price change	-11.26%
6M total return	-11.26%
All-time high	$21.20
All-time high date	2018-07-13
All-time low	$0.53
All-time low date	2025-05-16
Average true range (ATR)	$0.17
Average volume	1.8M
Beta (1Y)	1.49
Beta (2Y)	1
Beta (5Y)	0.22
Change from 52-week high	-37.28%
Change from 52-week low	146.43%
Change from all-time high	-83.09%
Change from all-time low	580.14%
Change from open	3.87%
Day's gap	-0.57%
Dollar volume	$4.5M
High price	$3.63
Low price	$3.48
Monthly RSI	46.36
Open price	$3.49
Position in 52-week range	100%
Premarket change	-0.57%
Premarket close	$3.51
Premarket price	$3.49
Premarket volume	1.3K
Previous close	$3.51
Price vs 150-day SMA	-9.13%
Price vs 20-day SMA	-1.38%
Price vs 200-day SMA	-10.29%
Price vs 50-day SMA	-10.02%
Relative volume	0.7
RSI	43.35
Sharpe ratio	1.26
Sharpe ratio (3Y)	0.1
Sharpe ratio (5Y)	-0.02
Sortino ratio	2.41
Sortino ratio (3Y)	0.21
Sortino ratio (5Y)	0.04
Volume	1.2M
Weekly RSI	46.27
YTD price change	6.38%
YTD total return	6.38%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	136.8M
Float percentage	82.76%
Shares change (QoQ)	0.29%
Shares change (YoY)	3.27%
Shares held by insiders	3.24%
Shares held by institutions	84.8%
Shares outstanding	165.2M
Short % of float	11.38%
Short % of shares	9.42%
Short ratio	7.8 days

Deeper analysis on IRWD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IRWD report

Is a complete IRWD research report available?

No complete published report is available for Ironwood Pharmaceuticals, Inc. (IRWD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Ironwood Pharmaceuticals, Inc. (IRWD)

Price

Financial snapshot

Fair-value bridge

Latest news · IRWD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IRWD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IRWD

Frequently asked questions